Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biota Pharmaceuticals Inc    NABI

 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 7,10 M
EBIT 2016 -27,6 M
Net income 2016 -27,5 M
Debt 2016 -
Yield 2016 -
Sales 2017 -
EBIT 2017 -
Net income 2017 -
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017 -
Capi. / Sales 2016 8,63x
Capi. / Sales 2017 -
Capitalization 61,2 M
More Financials
Company
Aviragen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening infectious diseases.The Company currently has two Phase 2 clinical-stage product candidates in development: laninamivir... 
More about the company
Latest news on BIOTA PHARMACEUTICALS INC
04/28 Aviragen Therapeutics to Host Conference Call to Report Third Quarter Fiscal ..
04/26 AVIRAGEN THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other ..
04/25 Aviragen Therapeutics Completes Royalty Deal With HealthCare Royalty Partners..
2012 NABI BIOPHARMACEUTICALS : Effects Reverse Stock Split and Announces the Completi..
2012 BIOTA PHARMACEUTICALS INC : ex-dividend day
2012 BIOTA PHARMACEUTICALS INC : REVERSE SPLIT: 1 of 6
2012 NABI BIOPHARMACEUTICALS : Announces Special Cash Dividend
2012 NABI BIOPHARMACEUTICALS : The Board of Nabi Biopharmaceuticals Establishes Ratio..
More news
Sector news : Bio Therapeutic Drugs
02:19p BRIEF : Sanofi girds for another fight
04/29 SANOFI : offers to buy Medivation for $9.3bn
04/29 SANOFI : France's Sanofi makes $9.3 billion bid for US cancer drug giant
More sector news : Bio Therapeutic Drugs
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions